Recent studies show approximately one in four blood cancer patients fail to produce detectable antibodies after COVID-19 vaccination. This is most prevalent in those hosting non-Hodgkin lymphomas and chronic lymphocytic leukemia, but also in those hosting multiple myeloma and other blood cancers.